These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 9238056

  • 1. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
    Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ.
    Proc Natl Acad Sci U S A; 1997 Aug 05; 94(16):8789-94. PubMed ID: 9238056
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-CD40 therapy extends renal allograft survival in rhesus macaques.
    Pearson TC, Trambley J, Odom K, Anderson DC, Cowan S, Bray R, Lin A, Hollenbaugh D, Aruffo A, Siadak AW, Strobert E, Hennigar R, Larsen CP.
    Transplantation; 2002 Oct 15; 74(7):933-40. PubMed ID: 12394833
    [Abstract] [Full Text] [Related]

  • 4. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody.
    Sun H, Subbotin V, Chen C, Aitouche A, Valdivia LA, Sayegh MH, Linsley PS, Fung JJ, Starzl TE, Rao AS.
    Transplantation; 1997 Dec 27; 64(12):1838-43. PubMed ID: 9422428
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of corneal allograft reaction by CTLA4-Ig.
    Hoffmann F, Zhang EP, Pohl T, Kunzendorf U, Wachtlin J, Bulfone-Paus S.
    Graefes Arch Clin Exp Ophthalmol; 1997 Aug 27; 235(8):535-40. PubMed ID: 9285225
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts.
    Fu F, Li W, Lu L, Thomson AW, Fung JJ, Qian S.
    Transplant Proc; 1999 Aug 27; 31(1-2):1244. PubMed ID: 10083555
    [No Abstract] [Full Text] [Related]

  • 8. Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection.
    Ardjomand N, McAlister JC, Rogers NJ, Tan PH, George AJ, Larkin DF.
    Invest Ophthalmol Vis Sci; 2003 Sep 27; 44(9):3899-905. PubMed ID: 12939307
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival.
    Comer RM, King WJ, Ardjomand N, Theoharis S, George AJ, Larkin DF.
    Invest Ophthalmol Vis Sci; 2002 Apr 27; 43(4):1095-103. PubMed ID: 11923251
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chronic CD40L blockade is required for long-term cardiac allograft survival with a clinically relevant CTLA4-Ig dosing regimen.
    Unger LW, Muckenhuber M, Mahr B, Schwarz C, Pilat N, Granofszky N, Regele H, Wekerle T.
    Front Immunol; 2022 Apr 27; 13():1060576. PubMed ID: 36569922
    [Abstract] [Full Text] [Related]

  • 13. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation.
    Montgomery SP, Xu H, Tadaki DK, Celniker A, Burkly LC, Berning JD, Cruzata F, Elster EA, Gray G, Kampen RL, Swanson SJ, Harlan DM, Kirk AD.
    Transplantation; 2002 Nov 27; 74(10):1365-9. PubMed ID: 12451232
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
    Zheng XX, Markees TG, Hancock WW, Li Y, Greiner DL, Li XC, Mordes JP, Sayegh MH, Rossini AA, Strom TB.
    J Immunol; 1999 Apr 15; 162(8):4983-90. PubMed ID: 10202046
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.